Ranolazine: an antianginal drug with antiarrhythmic properties

References

• Priori S, Zipes D. Sudden cardiac death. Blackwell Publishing Inc., Malden, MA, USA (2006).
   Google Scholar
• Prystowsky EN, Camm J, Lip GYH et al. The impact of new and emerging clinical data on treatment strategies for atrial fibrillation. J. Cardiovasc. Electrophysiol.21, 946–958 (2010).
   Google Scholar
• Marban E, Yamagishi T, Tomaselli GF. Structure and function of voltage-gated sodium channels. J. Physiol.508, 647–657 (1998).
   PubMed Web of Science ®Google Scholar
• Undrovinas AI, Maltsev VA, Kyle JW, Silvermann N, Sabbah HN. Gating of the late Na+ channel in normal and failing human myocardium. J. Mol. Cell. Cardiol.34, 1477–1489 (2002).
   Google Scholar
• Maltsev VA, Undrovinas AI. A multi-modal composition of the late Na+ current in human ventricular cardiomyocytes. Cardiovasc. Res.69, 116–127 (2006).
   PubMed Web of Science ®Google Scholar
• Saint DA. The cardiac persistent sodium current: an appealing therapeutic target? Br. J. Pharmacol.153, 1133–1142 (2008).
   PubMed Web of Science ®Google Scholar
• Zaza A, Belardinelli L, Shryock JC. Pathophysiology and pharmacology of the cardiac ‘late sodium current’. Pharmacol. Ther.119, 326–339 (2008).
   PubMed Web of Science ®Google Scholar
• Valvidia CR, Chu WW, Pu J, Foell JD, Haworth RA, Wolff MR et al. Increased late sodium current in myocytes from a canine heart failure model and from failing human heart. J. Mol. Cell. Cardiol.38, 475–483 (2005).
   Google Scholar
• Mugelli A, Tamargo J. Pharmacology of ranolazine. Ischemia begets ischemia: a new drug to interrupt the vicious cycle. Oxford Clinical Publishing, Oxford, UK (2009).
   Google Scholar
• Hammarström AK, Gage PW. Hypoxia and persistent sodium current. Eur Biophys. J.31, 323–330 (2002).
   Google Scholar
• Undrovinas AI, Maltsev VA, Sabbah HN. Repolarization abnormalities in cardiomyocytes of dogs with chronic heart failure: role of sustained inward current. Cell. Mol. Life Sci.55, 494–505 (1999).
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur. Heart J.6, 13–17 (2004).
   Web of Science ®Google Scholar
• Antzelevitch C, Belardinelli L, Zygmunt AC et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation110, 904–910 (2004).
   PubMed Web of Science ®Google Scholar
• Noble D, Noble PJ. Late sodium current in the pathophysiology of cardiovascular disease: consequences of sodium–calcium overload. Heart92, iv1–iv5 (2006).
   PubMed Web of Science ®Google Scholar
• Sossalla S, Kallmeyer B, Wagner S et al. Altered Na+ currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J. Am. Coll. Cardiol.55, 2330–2342 (2010).
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Burashnikov A, Sicouri S, Belardinelli L. Electrophysiological basis for the antiarrhythmic actions of ranolazine. Heart Rhythm. DOI: 10.1016/j.hrthm.2011.03.045 (2011) (Epub ahead of print).
   Google Scholar
• Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ. Res.71, 1231–1241 (1992).
   PubMed Web of Science ®Google Scholar
• Wu J Corr PB. Palmitoyl carnitine modifies sodium currents and induces transient inward current in ventricular myocytes. Am. J. Physiol.266, H1034–H1046 (1994).
   Google Scholar
• Ma JH, Luo AT, Zhang PH. Effect of hydrogen peroxide on persistent sodium current in guinea pig ventricular myocytes. Acta Pharmacol. Sin.26, 828–834 (2005).
   Google Scholar
• Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J. Pharmacol. Exp. Ther.318, 214–222 (2006).
   PubMed Web of Science ®Google Scholar
• Ahern GP, Hsu SF, Klyachko VA, Jackson MB. Induction of persistent sodium current by exogenous and endogenous nitric oxide. J. Biol. Chem.275, 28810–28815 (2000).
   PubMed Web of Science ®Google Scholar
• Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. J. Mol. Cell. Cardiol.44, 954–967 (2008).
   PubMed Web of Science ®Google Scholar
• Belardinelli L, Shryock JC, Fraser H. The mechanism of ranolazine action to reduce ischemia-induced diastolic dysfunction. Eur. Heart J.8(Suppl. A), A10–A13 (2006).
   Web of Science ®Google Scholar
• Wu L, Shryock JC, Song Y, Belardinelli L. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J. Pharmacol. Exp. Ther.316, 718–726 (2006).
   Google Scholar
• Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the proarrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J. Cardiovasc. Pharmacol.44, 192–199 (2004).
   PubMed Web of Science ®Google Scholar
• Fraser H, Belardinelli L, Wang L, Light PE, McVeigh JJ, Clanachan AS. Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts. J. Mol. Cell. Cardiol.41, 1031–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Song Y, Shryock JC, Belardinelli L. An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes. Am. J. Physiol. Heart Circ. Physiol.294, H2031–H2039 (2008).
   PubMed Web of Science ®Google Scholar
• Wu L, Rajamani S, Li H, January CT, Shryock JC, Belardinelli L. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na+ current in the heart. Am. J. Physiol. Heart Circ. Physiol.297, H1048–H1057 (2009).
   PubMed Web of Science ®Google Scholar
• Maack C, Cortassa S, Aon MA, Ganesan AN, Liu T, O’Rourke B. Elevated cytosolic Na+ decreases mitochondrial Ca2+ uptake during excitation-contraction coupling and impairs energetic adaptation in cardiac myocytes. Circ. Res.99, 172–182 (2006).
   PubMed Web of Science ®Google Scholar
• Kohlhaas M, Liu T, Knopp A et al. Elevated cytosolic Na+ increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation121, 1606–1613 (2010).
   PubMed Web of Science ®Google Scholar
• Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation113, 2462–2472 (2006).
   PubMed Web of Science ®Google Scholar
• Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs68, 2483–2503 (2008).
   PubMed Web of Science ®Google Scholar
• Rajamani S, El-Bizri N, Shryock JC, Makielski JC, Belardinelli L. Use-dependent block of cardiac late Na+ current by ranolazine. Heart Rhythm6, 1625–1631 (2009).
   PubMed Web of Science ®Google Scholar
• Undrovinas AI, Belardinelli L, Undrovinas NA, Sabbah HN. Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J. Cardiovasc. Electrophysiol.17(Suppl. 1), S169–S177 (2006).
   PubMedGoogle Scholar
• Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br. J. Pharmacol.42, 1300–1308 (2004).
   Google Scholar
• Rajamani S, Shryock JC, Belardinelli L. Mechanism of ranolazine block of cardiac Na channels. Eur. Heart J.28, 400 (2007).
   Google Scholar
• Wang GK, Calderon J, Wang SY. State- and use-dependent block of muscle Nav1. 4 and neuronal Nav1. 7 voltage-gated Na+ channel isoforms by ranolazine. Mol. Pharmacol.73, 940–948 (2008).
   PubMed Web of Science ®Google Scholar
• Zygmunt AC, Nesterenko VV, Rajamani S et al. Mechanism of the preferential block of the atrial sodium current by ranolazine. Biophys. J.96(Suppl.), 250a (2009).
   Google Scholar
• Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J. Pharmacol. Exp. Ther.310, 599–605 (2004).
   PubMed Web of Science ®Google Scholar
• Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br. J. Pharmacol.148, 16–24 (2006).
   PubMed Web of Science ®Google Scholar
• Sossalla S, Wagner S, Rasenack ECL et al. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts: role of late sodium current and intracellular ion accumulation. J. Mol. Cell. Cardiol.45, 32–43 (2008).
   PubMed Web of Science ®Google Scholar
• Huang H, Priori SG, Napolitano C, O’Leary ME, Chahine M. Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1. 5 channels. Am. J. Physiol. Heart Circ. Physiol.300, H288–H299 (2011).
   Google Scholar
• Rajamani S, Shryock JC, Belardinelli L. Rapid kinetic interactions of ranolazine with HERG K+ current. J. Cardiovasc. Pharmacol.51, 581–589 (2008).
   PubMed Web of Science ®Google Scholar
• Soliman D, Wang L, Hamming KSC et al. Inhibition of reverse-mode sodium-calcium exchange by the anti-anginal agent ranolazine. FASEB J.24, 961–969 (2010).
   Google Scholar
• Burashnikov A, Di Diego JM, Zygmunt AC, Belardinelli L, Antzelevitch C. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation. Circulation116, 1449–1457 (2007).
   PubMed Web of Science ®Google Scholar
• Allen TJ, Chapman RA. Effects of ranolazine on L-type calcium channel currents in guinea-pig single ventricular myocytes. Br. J. Pharmacol.118, 249–254 (1996).
   PubMed Web of Science ®Google Scholar
• Zhao G, Walsh E, Shryock J et al. Anti-adrenergic and hemodynamic effects of ranolazine in conscious dogs. J. Cardiovasc. Pharmacol.57, 639–647 (2011).
   PubMed Web of Science ®Google Scholar
• Sicouri S, Glass A, Belardinelli L, Antzelevitch C. Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm5, 1019–1026 (2008).
   PubMed Web of Science ®Google Scholar
• Shtyock JC, Belardinelli L. Inhbition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium. Br. J. Pharmacol.153, 1133–1142 (2008).
   Google Scholar
• Belardinelli L, Antzelevitch C, Vos M. Potential predictors of drug-induced torsade de pointes: early afterdepolarizations, ectopic beats and increased dispersion of ventricular repolarization. TIPS24, 619–625 (2003).
   PubMed Web of Science ®Google Scholar
• Wu L, Ma J, Li H et al. Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation123, 1713–1720 (2011).
   PubMed Web of Science ®Google Scholar
• Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2, 6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J. Pharmacol. Exp. Ther.325, 875–881 (2008).
   Google Scholar
• Antoons G, Oros A, Beekman JD et al. Late Na+ current inhibition by ranolazine reduces torsades de pointes in the chronic atrioventricular block dog model. J. Am. Coll. Cardiol.55, 801–809 (2010).
   PubMed Web of Science ®Google Scholar
• Wu J, Cheng L, Lammers WJ et al. Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine. Prog. Biophys. Mol. Biol.98, 198–207 (2008).
   Google Scholar
• Dhalla AK, Wang WQ, Dow J et al. Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion. Am. J. Physiol. Heart Circ. Physiol.297, H1923–H1929 (2009).
   Google Scholar
• Kloner RA, Dow JS, Bhandari A. First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. J. Cardiovasc. Pharmacol. Ther. DOI: 10.1177/1074248410386485 (2010) (Epub ahead of print).
   Google Scholar
• Morita N, Lee JH, Xie Y et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J. Am. Coll. Cardiol.57, 366–375 (2011).
   PubMed Web of Science ®Google Scholar
• Kumar K, Nearing BD, Cartoli CR, Kwaku KF, Belardinelli L. Effect of ranolazine on ventricular vulnerability and defibrillation threshold in the intact porcine heart. J. Cardiovas. Electrophysiol.19, 1073–1079 (2008).
   Google Scholar
• Nieminen T, Nanbu DY, Datti IP et al. Antifibrillatory effect of ranolazine during severe coronary stenosis in the intact porcine model. Heart Rhythm.8, 608–614 (2011).
   Google Scholar
• Kumar K, Nearing BD, Carvas M et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J. Cardiovasc. Electrophysiol.20, 796–802 (2009).
   PubMed Web of Science ®Google Scholar
• Carvas M, Nascimento BC, Acar M, Nearing BD, Belardinelli L, Verrier RL. Intrapericardial ranolazine prolongs atrial refractory period and markedly reduces atrial fibrillation inducibility in the intact porcine heart. J. Cardiovasc. Pharmacol.55, 286–291 (2010).
   PubMed Web of Science ®Google Scholar
• Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J. Am. Coll. Cardiol.56, 1216–1224 (2010).
   PubMed Web of Science ®Google Scholar
• Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ. Arrhythm. Electrophysiol.3, 88–95 (2010).
   PubMed Web of Science ®Google Scholar
• Scirica BM, Morrow DA, Hod H et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation116, 1647–1652 (2007).
   PubMed Web of Science ®Google Scholar
• Morrow DA, Scirica BM, Karwatowska-Prokopczuk E et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA297, 1775–1783 (2007).
   PubMed Web of Science ®Google Scholar
• Murdock DK, Overton N, Kersten M, Kaliebe J, Devecchi F. The effect of ranolazine on maintaining sinus rhythm in patients with resistant atrial fibrillation. Indian Pacing Electrophysiol. J.8, 175–181 (2008).
   PubMedGoogle Scholar
• Miles RH, Murdock DK. Ranolazine verses amiodarone for prophylaxis against atrial fibrillation following coronary artery bypass surgery. Heart Rhythm7, S258 (2010).
   Google Scholar
• Murdock DK, Kersten M, Kaliebe J, Larrain G. The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible ‘pill in the pocket’ approach to atrial fibrillation. Indian Pacing Electrophysiol. J.9, 260–267 (2009).
   PubMedGoogle Scholar
• Murdock DK, Reiffel JA, Kaliebe J et al. The conversion of paroxysmal or initial onset atrial fibrillation with oral ranolazine: implications for a new ‘pill-in-pocket’ approach in structural heart disease. JFIB2, 705–710 (2011).
   Google Scholar
• Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J. Cardiovasc. Electrophysiol.19, 1289–1293 (2008).
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am. J. Cardiol.95, 311–316 (2005).
   PubMed Web of Science ®Google Scholar
• Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc. Drugs Ther.8, 741–747 (1994).
   PubMed Web of Science ®Google Scholar
• Bennett PB, Yazawa K, Makita N, George AL Jr. Molecular mechanism for an inherited cardiac arrhythmia. Nature376, 683–685 (1995).
   PubMed Web of Science ®Google Scholar
• Lindegger N, Hagen BM, Marks AR, Lederer WJ, Kass RS. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J. Mol. Cell. Cardiol.47, 326–334 (2009).
   PubMed Web of Science ®Google Scholar
• Splawski I, Timothy KW, Sharpe LM et al. Ca(V)1. 2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell.1, 19–31 (2004).
   Google Scholar
• Sicouri S, Timothy KW, Zygmunt AC et al. Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm4, 638–647 (2007).
   PubMed Web of Science ®Google Scholar
• Shah DP, Baez-Escudero JL, Weisberg IL, Beshai JF, Burke MC. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing Clin. Electrophysiol. DOI: 10.1111/j. 1540–8159.2010.02913.x. (2010) (Epub ahead of print).
   Google Scholar